ENTITY
Astellas Pharma

Astellas Pharma (4503 JT)

9
Analysis
Health Care • Japan
Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fields of urology, immunology including transplantation and infectious diseases, oncology, euroscience and DM complications and metabolic diseases. The Company researches, develops, manufactures, and promotes its prescription drugs through subsidiaries in the US, Europe, and Asia.
more
bullish•Astellas Pharma
•23 Dec 2016 15:01

Xtandi (Enzalutamide) – Second Generation Androgen Receptor (AR) Signalling Inhibitor

While most of its peers struggle getting traction with new launches, Astellas is in a fortunate situation with its recently launched prostate...

•13 Dec 2016 11:44

American Society of Hematology- (ASH) Annual Conference (2016) Review

We reviewed data presented at the American Society of Hematology (ASH) conference in San Diego last week with a focus on the evolving treatment...

•03 Dec 2016 18:43

American Society of Hematology (ASH) -Annual Conference (2016) Preview

With a focus on novel mechanisms of action (MoA), we highlight select non-Hodgkin's lymphoma (NHL) and Multiple Myeloma (MM) related abstracts at...

•23 Nov 2016 12:20

Buoyant Returns Beyond the Benchmark in 2016 YTD

The first 10 months of 2016 brought its fair share of macroeconomic challenges to the region. During the 10 months, the Straits Times Index (STI)...

Share
•23 Nov 2016 12:14

Why Hold Japan, Part II: Comparative Valuation Among G7 Economies

"Why Hold Japan?" is a question that recurs among foreign investors, now the greatest cohort of investors in Japanese stocks.  The question tends...

Logo
330 Views
Share
x